Post on 17-Dec-2015
transcript
2
• Plasmin: It is the protease enzyme present in our blood
which brings about lysis of clot or fibrin • Plasminogen: It is the inactive precursor of plasmin On activation it gets converted to active plasmin
4
Tissue plasminogen activator:• It is the enzyme in the body which activates & converts
plasminogen to plasmin • It is released when there is stasis of blood
formation of clots in blood t plasminogen activator
Plasminogen Plasmin• α 2 Antiplasmin :
It terminates the action of t PA after dissolution of pathological clots in our blood.
6
• Thrombolytic drugs:• All these drugs are plasminogen activators -
When given in large doses they overcome the action of anti-plasmin and dissolve thrombi
• The fibrin degradation products also inactivate anti-plasmin
• When plasminogen activators are administered for thrombolytic therapy massive fibrinolysis is initiated and the inhibitory controls are overwhelmed
7
• Streptokinase:• It is a protein (protease enzyme) produced by ß
hemolytic streptococci• It has no intrinsic enzymatic activity • But forms a stable non-covalent complex with
proactivator plasminogen• This produces a conformational change that
catalyzes the following conversion plasminogen plasmin
8
• It has to be given in a loading dose of 250,000 units to overcome plasma antibodies (from prior streptococcal infection)
• ½ life is 40-80 minutes• The streptokinase - plasminogen complex is not
inhibited by α 2 antiplasmin• ADRs: Allergic reactions Fever AnaphylaxisPrior presence of antistreptococcal antibodies may
↓ efficacy. Hence it cannot be repeated before one year of prior strep. Infection.
9
• Urokinase:• A protease enzyme isolated from cultured
human kidney cells. It is a direct plasminogen activator.
• ½ life is 15-20 minutes. • It is non antigenic, non pyrogenic, non allergic,
does not produce hypotension. • It is given in a loading dose of 300,000 U over 10
minutes followed by maintenance dose of 300,000 units/hour over 12 hrs
• Used instead of streptokinase and in whom streptokinase cannot be repeated.
10
Recombinant tissue plasminogen activator (Alteplase):
• It is manufactured by recombinant DNA technology.
• It is a poor plasminogen activator in the absence of fibrin.
• It preferentially activates bound plasminogen several hundred fold more rapidly than plasminogen in the circulation.
• It is effective in lysing thrombi during ACUTE MYOCARDIAL INFARCTION.
11
• Seems superior to streptokinase and urokinase in dissolving old clots.
• As effective as streptokinase but safer (more expensive). Minimal antigenicity.
• It is given as a bolus intravenously• 15 mg followed by 0.75 mg/kg over 30
minutes.
12
Anistreplase (APSAC):• It consists of a complex of purified human plasminogen
and bacterial streptokinase that has been acetylated to protect the active site of plasminogen.
• When administered the acyl group spontaneously hydrolyses freeing the activated streptokinase proactivator complex to perform fibrinolysis.
• This allows for rapid IV injection, greater clot selectivity i.e. more active on plasminogen associated with clots than free plasminogen – more thrombolytic activity
• Dose: 30 units as a single intravenous injection given over 3-5 minutes
13
Therapeutic uses:• Myocardial infarction• Severe pulmonary embolism• Deep vein thrombosis• Acute peripheral arterial occlusion
14
ADRs:• Bleeding - commonest ADR• Less with selective agents – r tPA• Allergic reactions: Streptokinase – bacterial protein antigenic Rarely anaphylactic reactions seen • Hypotension: with rapid administration of streptokinase.• Hemorrhagic stroke
15
Absolute contraindications to thrombolytic therapy:
• Prior intracranial hemorrhage• Known structural cerebral vascular lesion• Known malignant intracranial neoplasm• Ischemic stroke within 3 months• Suspected aortic dissection• Active bleeding or bleeding diathesis• Significant head trauma or facial trauma
within 3 months.
16
Relative contraindications to thrombolytic therapy:
-Major surgery, traumatic or prolonged CPR within 3 weeks.
-Recent (within 2-4 weeks)internal bleeding-pregnancy - Non compressible vascular punctures- Severe uncontrolled hypertension (SBP > 180
mmHg or DBP> 110mmHg) Active pepetic ulcer Current use of warfarin and INR > 1.7
18
Epsilon aminocaproic acid (EACA):• It is chemically similar to the amino acid lysine• It is a synthetic inhibitor of fibrinolysis• It competitively inhibits plasminogen activation • Rapidly absorbed orally• Cleared by the kidneys• Dosage: 6 g four times daily
19
Tranexamic acid:• It is an analog of aminocaproic acid and has
the same properties • It is administered orally with a 15mg/kg
loading dose followed by 30 mg/kg every 6 hours
20
Uses:1. Adjuvant therapy in hemophilia2. Treatment of bleeding from fibrinolytic
therapy 3. Prophylaxis for re-bleeding from intracranial
aneurysms 4. Post surgical GI bleeding5. Post prostatectomy bleeding6. Bladder hemorrhages secondary to radiation
or drug induced cystitis
21
Aprotinin: (Serine protease inhibitor)It is a serine protease inhibitorIt inhibits fibrinolysis by free plasminIt may have other anti-hemorrhagic effects as wellIt ↓ bleeding by 50% from many types of surgery - heart procedures
- liver transplantationIt is currently approved for patients undergoing CABG
who are at high risk of excessive bleedingADRs: Recent studies have shown - ↑ risk of MI, stroke & renal damageAssociation with anaphylaxis also noted - test dose
required
22
LOCAL HAEMOSTATICS (STYPTICS)
• These drugs are used to stop bleeding from oozing locations
• eg. tooth sockets, open wounds.• They are meant only for local application • Most of them provide a network of fibrin
which promotes coagulation
23
Thrombin:• Obtained from bovine plasma. • Applied topically it is a good haemostaticFibrin sealant:• Obtained from human plasma• Used to stop microbleeding & oozing in dental
procedures Gelatin foams:• Soaked with saline, fibrin or thrombin to cover or pack
bleeding surfaces.Vasoconstrictors: • 1% adrenaline soaked gauze effective haemostatic